Cadence Pharmaceuticals

Focused on in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting. The company’•s lead product is OFIRMEV, a patent-protected intravenous (IV) formulation of acetaminophen.  In February 2014, Cadence was acquired by Mallinckrodt for $1.3 billion.